

# Glenmark's blood cancer drug ISB 2001 shows promising results in trial

## Synopsis

Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.



Representative Image

Ichnos Glenmark Innovation, a clinical stage biotechnology company focused on oncology, has announced promising results for an innovative drug used for the treatment of relapsed or refractory multiple myeloma (RRMM), a rare form of blood cancer that affects plasma cells in bone marrow.

Coded ISB 2001, the drug demonstrated an overall response rate (ORR) of 79% in a Phase 1 global study based on finding from patients who were administered a recommended dose. Patients who had exhausted other

## News Source:

<https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmarks-blood-cancer-drug-isb-2001-shows-promising-results-in-trial/articleshow/121577554.cms?from=mdr>